surmount 4 tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial Media Centre | EASD

5, Nov 1998, pp

Ozempic works through multiple metabolic pathways: This multi-target action explains why Ozempic helps with both diabetes and weight control

EVOKE+: Testing semaglutide but expanding to a broader population, allowing participants who have extensive small blood vessel damage in the brain

Preliminary research shows that better glucose metabolism and decreased inflammation can lower the risk of neurodegenerative diseases such as Alzheimers disease

Lean patients with MetALD face higher liver and death risks, study finds by Matthew Solan A retrospective VA cohort links lean MetALD to an 82% higher risk of all-cause mortality versus overweight or obese patients

Difficulty weight-bearing